

Comorbidities, biomarkers and severe COVID-19

Inclusion criteria

- 18+** Age >18 years-old
- Symptomatic hospitalized patients**
- Confirmed SARS-CoV-2 infection**
- Informed consent**

N= 336 patients

**Non severe
253 (75%)**

**Severe
83 (25%)**

ASSOCIATED WITH SEVERITY

CHARACTERISTICS and COMORBIDITIES

- Age**
- Male sex**
- Obesity**
- Obstructive sleep apnea**



BIOMARKERS

- LDH >600 U/L**
- Serum ferritin >500 mcg/L**
- Interleukin-6 >40 pg/mL**




Prevalence of cardiac amyloidosis in heart failure (PREVAMIC)

Inclusion criteria

-  Age ≥ 65 years-old
-  HF diagnosis (ESC 2016 Guidelines)
-  Internal Medicine: inpatients or outpatients
-  LVEF: any value
-  LVH: septum or posterior wall > 12 mm
-  NYHA class II-IV
-  Diuretic treatment in the last 6 months
-  Elevated natriuretic peptides
-  Informed consent



Inclusion visit



One-year follow-up visit



ATTR: transthyretin amyloidosis; ED: Emergency Departments; ESC: European Society of Cardiology; FLCs: free light chains; HF: heart failure; IFE: immunofixation electrophoresis; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; NYHA: New York Heart Association; TTR: transthyretin.